Bayer, Sysmex link to concoct companion Dx for targeted tumor treatments

Bayer, the German drugmaker, will join forces with Japanese diagnostics giant Sysmex to develop companion diagnostic tests for targeted cancer tumor treatments. Specifically, Sysmex's newly acquired Inostics division will develop blood-based companion diagnostic tests to be paired with targeted anticancer drugs advanced by Bayer HealthCare. They'll rely heavily on Sysmex Inostics' BEAMing technology that enables creation of extremely sensitive diagnostic tests that can screen for circulating tumor DNA cast off into the bloodstream. Neither side is disclosing financial details. Story

Suggested Articles

J&J launched a virtual clinical study to gauge whether Apple’s iPhone and ECG-enabled smartwatch can help reduce the risk of stroke and catch AFib.

The Salt Lake City-based developer said its Logix Smart test is now available to be exported from Utah to countries requiring the CE Mark.

Dexcom received a new European approval for its wearable continuous glucose monitor in pregnant women across Type 1, Type 2 and gestational diabetes.